Literature DB >> 20129875

The estimated incidence of gastrointestinal stromal tumors in France. Results of PROGIST study conducted among pathologists.

Geneviève Monges1, Ségolène Bisot-Locard, Jean-Yves Blay, Anne-Marie Bouvier, Marisol Urbieta, Jean-Michel Coindre, Jean-Yves Scoazec.   

Abstract

UNLABELLED: The aim of this study was to investigate the incidence of gastrointestinal stromal tumors (GISTs) in France.
METHOD: This prospective epidemiological study was performed among pathologists who were asked to report exhaustively the cases of GIST over a one-year period.
RESULTS: Five hundred ninety-one cases of GISTs were reported, 535 new cases and 56 cases of relapse. So, the estimated incidence of GIST in France was 8.5-10 cases per million inhabitants in 2005. The main characteristics of the new GIST cases were as follows: mean age 65 (+/- 13.2) years; 48.6% men; circumstances of discovery: fortuitous 30.5%, symptomatic 46.5%, and unknown 23%. The primary tumor locations were stomach 63.7%, small intestine 21.5%, mesentery 6.5%, colon and rectum 3.2%, esophagus 0.7%, and 4.3% locations were listed as unknown. Globally, 95.3% of GISTs were cKIT (CD117) positive. Based on tumor size and mitotic rate, among the 490 localized GISTs, 14.7% were considered to have a very low prognostic risk, 25.5% low risk, 23.1% intermediate risk, and 23.1% high risk.
CONCLUSIONS: This study provides for the first time an estimation of the incidence of GISTs in France, and the results are comparable to what has been reported in studies in other European countries.

Entities:  

Mesh:

Year:  2010        PMID: 20129875     DOI: 10.1684/bdc.2010.1041

Source DB:  PubMed          Journal:  Bull Cancer        ISSN: 0007-4551            Impact factor:   1.276


  21 in total

1.  Gastrointestinal stromal tumors of the esophagus: evaluation of a pooled case series regarding clinicopathological features and clinical outcome.

Authors:  Simon Lott; Michael Schmieder; Benjamin Mayer; Doris Henne-Bruns; Uwe Knippschild; Abbas Agaimy; Matthias Schwab; Klaus Kramer
Journal:  Am J Cancer Res       Date:  2014-12-15       Impact factor: 6.166

2.  Huge esophageal gastrointestinal stromal tumor successfully resected under mediastino-laparoscopic transhiatal esophagectomy: a case report.

Authors:  Keisuke Mishima; Takeshi Matsutani; Ryo Yamagiwa; Hidetsugu Hanawa; Yuji Kurihara; Norio Motoda; Nobuhiko Taniai; Hiroshi Yoshida
Journal:  Surg Case Rep       Date:  2022-06-06

3.  Cost-Effectiveness Analysis of Tyrosine Kinase Inhibitors for Patients with Advanced Gastrointestinal Stromal Tumors.

Authors:  Virginie Nerich; Camille Fleck; Loïc Chaigneau; Nicolas Isambert; Christophe Borg; Elsa Kalbacher; Marine Jary; Pauline Simon; Xavier Pivot; Jean-Yves Blay; Samuel Limat
Journal:  Clin Drug Investig       Date:  2017-01       Impact factor: 2.859

4.  Coexistence of gastrointestinal stromal tumors and gastric adenocarcinomas.

Authors:  Yan Yan; Ziyu Li; Yiqiang Liu; Lianhai Zhang; Jiyou Li; Jiafu Ji
Journal:  Tumour Biol       Date:  2013-01-03

5.  Clinicopathologic features and outcomes of gastrointestinal stromal tumors arising from the esophagus and gastroesophageal junction.

Authors:  Andrew M Briggler; Rondell P Graham; Gustavo F Westin; Andrew L Folpe; Dawn E Jaroszewski; Scott H Okuno; Thorvardur R Halfdanarson
Journal:  J Gastrointest Oncol       Date:  2018-08

6.  Duodenal GIST: a single center experience.

Authors:  Alexander Beham; Inga-Marie Schaefer; Silke Cameron; Katharina von Hammerstein; Laszlo Füzesi; Giuliano Ramadori; Michael B Ghadimi
Journal:  Int J Colorectal Dis       Date:  2012-02-22       Impact factor: 2.571

7.  Sunitinib treatment for multiple brain metastases from jejunal gastrointestinal stromal tumor: case report.

Authors:  Hayato Takeuchi; Hiroshi Koike; Tomoaki Fujita; Hitoshi Tsujino; Yoshihiro Iwamoto
Journal:  Neurol Med Chir (Tokyo)       Date:  2013-11-20       Impact factor: 1.742

8.  Association of high expression of Groβ with clinical and pathological characteristics of unfavorable prognosis in gastrointestinal stromal tumors.

Authors:  Hui Zhao; Huijun Zhu; Qin Jin; Shu Zhang; Wei Wang; Defeng Wang; Jianfei Huang
Journal:  Dis Markers       Date:  2015-04-07       Impact factor: 3.434

9.  Extended adjuvant therapy with imatinib in patients with gastrointestinal stromal tumors : recommendations for patient selection, risk assessment, and molecular response monitoring.

Authors:  Piotr Rutkowski; Joanna Przybył; Marcin Zdzienicki
Journal:  Mol Diagn Ther       Date:  2013-02       Impact factor: 4.074

10.  Metachronous Primary Adenocarcinoma of Lung During Adjuvant Imatinib Mesylate Therapy for Gastrointestinal Stromal Tumor of Stomach: A Case Report.

Authors:  Meng-Jie Jiang; Shan-Shan Weng; Ying Cao; Xiao-Fen Li; Liu-Hong Wang; Jing-Hong Xu; Ying Yuan
Journal:  Medicine (Baltimore)       Date:  2015-09       Impact factor: 1.817

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.